Search Results for:

We are a team of highly driven pharmaceutical professionals who are passionate in our mission to address unmet needs for patients.

Phathom Pharmaceuticals is a late clinicalstage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders.

Phathom Pharmaceuticals is currently evaluating vonoprazan* (potassium-competitive acid blocker) vs active comparator lansoprazole (protein-pump inhibitor)

Phathom Pharmaceuticals is working to change the GI treatment landscape and improve the lives of patients with acid-related disorders.

A late clinical-stage biopharmaceutical company committed to transforming the treatment landscape for people suffering from GI diseases related to acid.

Find out where we are located, and how to contact us.

GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract.

H. pylori is a bacterial pathogen that infects approximately 35% of the U.S. population.

false